Uplinza® (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease

Originally developed at Duke, Amgen’s UPLIZNA® secures FDA approval as the first treatment for IgG4-related disease, achieving an 87% reduction in flare risk through CD19+ B-cell targeting.